Osteogenic Growth Peptide (10-14) is a truncated pentapeptide fragment of the active osteogenic growth peptide (OGP) and is a Src kinase (Src) inhibitor [1-2]. Osteogenic Growth Peptide (10-14) binds to the OGP receptor and activates the Gi protein-MAP kinase signaling pathway [3]. Osteogenic Growth Peptide (10-14) is a potent mitogen and bone formation and hematopoietic stimulator, which can be used to treat osteoporosis and periodontitis [4].
In vitro, Osteogenic Growth Peptide (10-14) (0.01, 0.1, 1, 10, and 100nM; 1, 5, and 7 days) treated human periodontal ligament stem cells (hPDLSCs), and at low concentrations (0.01, 0.1, and 1nM), it significantly enhanced cell proliferation and osteogenic differentiation potential, while at concentrations of 10 and 100nM, there was no related response [5]. Osteogenic Growth Peptide (10-14) (0.1nM; 7-21 days) treatment significantly promoted osteogenic differentiation of bone marrow mesenchymal stem cells (MSCs), inhibited adipocyte formation, increased alkaline phosphatase (ALP) activity and mineralization nodules formation, and stimulated osteoblast-specific mRNA expression of nuclear factor 1 (cbfa1), and inhibited adipocyte-specific mRNA expression of peroxisome proliferator-activated receptor gamma-2 (PPARγ2) [6].
In vivo, Osteogenic Growth Peptide (10-14) (1nmol/kg/day; 35 days; s.c.) could significantly alleviate bone loss in female mice that underwent ovarian removal (OVX) 30 days before the start of anabolic therapy, and increase the number of osteogenic cells in the mice [7].
References:
[1] Chen YC, et al. Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP(10-14). J Med Chem. 2002;45(8):1624-1632.
[2] Battolla B, et al. The small peptide OGP(10-14) reduces proliferation and induces differentiation of TPO-primed M07-e cells through RhoA/TGFbeta1/SFK pathway. Med Sci Monit. 2011;17(1):SC1-SC5.
[3] Chen Z, et al. Regulation of endochondral ossification by osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)]. Protein Pept Lett. 2009;16(9):1074-1080.
[4] Fazzi R, et al. Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice. Leuk Res. 2002;26(1)
[5] Purbantoro S D, Osathanon T, Nantavisai S, et al. Osteogenic growth peptide enhances osteogenic differentiation of human periodontal ligament stem cells[J]. Heliyon, 2022, 8(7).
[6] Chen ZX, Chang M, Peng YL, et al. Osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)] acts on rat bone marrow mesenchymal stem cells to promote differentiation to osteoblasts and to inhibit differentiation to adipocytes. Regul Pept. 2007;142(1-2):16-23.
[7] Bab I, Chorev M. Osteogenic growth peptide: from concept to drug design[J]. Peptide Science: Original Research on Biomolecules, 2002, 66(1): 33-48.